Core Points - The company guarantees the authenticity, accuracy, and completeness of the quarterly report, with no false records or misleading statements [2][3] - The financial report for the third quarter of 2025 has not been audited [3][5] - The net profit attributable to the parent company's shareholders, after deducting the impact of share-based payments, is 140,748,079.80 yuan [3][4] Financial Data - The company reported a loss of 8,321,702.80 yuan due to share-based payments for the period from January to September 2025 [3] - There are no non-recurring profit and loss items applicable for the reporting period [4] - The company has not reclassified any non-recurring profit and loss items as recurring [4] Shareholder Information - The company has experienced changes in the number of shareholders and their holdings, but specific details are not applicable for this report [4] - There are no changes in the top ten shareholders due to securities lending activities [4] Other Important Matters - No other significant matters are reported for the quarter [4]
北京百普赛斯生物科技股份有限公司2025年第三季度报告